Ambrish Mithal | |
|---|---|
| Born | 29 March 1958 Lucknow, India |
| Alma mater | GSVM Medical College |
| Occupations |
|
| Years active | 27 |
| Known for | Endocrinology |
| Awards | |
| Website | web site |
Ambrish Mithal is an Indian endocrinologist and diabetologist. [1] [2] He secured MBBS from GSVM Medical College, master's degree (DM) from the All India Institute of Medical Sciences, New Delhi. Then he worked at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow [3] and, later, at Apollo Hospitals, New Delhi [4] before joining Medanta the Medicity as Chairman, Division of Endocrinology and Diabetes [4] [1] where he worked from 2009 to 2019. Subsequently, he joined Max Health Care where he serves as the chairman and head of Endocrinology and Diabetes department. [5] [6]
Mithal, who has published a number of articles in the field of endocrinology in prestigious journals, [7] [8] was honoured by the Government of India in 2015 with Padma Bhushan, the third highest Indian civilian award, for his outstanding contribution to the field of medicine. [9] [10] In September 2020, Mithal became the first Indian to be chosen for the Laureate Award for International Excellence in Endocrinology (2021) by the Endocrine Society (US). [11] [12] Mithal was awarded the International Osteoporosis Foundation President's award in March 2016. [13] In March 2017, Mithal was awarded the Dr. B. C. Roy Award by the President of India (for the year 2015) for his contribution to the development of endocrinology in India. [14] [15] He is also a recipient of the Fogarty Fellowship of Harvard Medical School (1992-93), JICA fellowship (1996), Boy Frame Award of the American Society for Bone and Mineral Research (2004), IOF Amgen Health Professionals Award (2005) and the Indian Medical Association Academy of Medical Sciences Award (2007). [3] He is also a fellow of the American Society for Bone and Mineral Research. [16]
Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones; it typically results from a pituitary adenoma. In children with hyperpituitarism, disruption of growth regulation is rare, either because of hormone hypersecretion or because of manifestations caused by local compression of the adenoma.
Stress hormones are secreted by endocrine glands to modify one's internal environment during the times of stress. By performing various functions such as mobilizing energy sources, increasing heart rate, and downregulating metabolic processes which are not immediately necessary, stress hormones promote the survival of the organism. The secretions of some hormones are also downplayed during stress. Stress hormones include, but are not limited to:
Endocrine diseases are disorders of the endocrine system. The branch of medicine associated with endocrine disorders is known as endocrinology.
Postpartum thyroiditis refers to thyroid dysfunction occurring in the first 12 months after pregnancy and may involve hyperthyroidism, hypothyroidism or the two sequentially. According to the National Institute of Health, postpartum thyroiditis affects about 8% of pregnancies. There are, however, different rates reported globally. This is likely due to the differing amounts of average postpartum follow times around the world, and due to humans' own innate differences. For example, in Bangkok, Thailand the rate is 1.1%, but in Brazil it is 13.3%. The first phase is typically hyperthyroidism. Then, the thyroid either returns to normal or a woman develops hypothyroidism. Of those women who experience hypothyroidism associated with postpartum thyroiditis, one in five will develop permanent hypothyroidism requiring lifelong treatment.
18-Hydroxycorticosterone is an endogenous steroid. It is a derivative of corticosterone.
1D-chiro-Inositol is a member of a family of related substances often referred to collectively as "inositol", although that term encompasses several isomers of questionable biological relevance, including 1L-chiro-inositol. myo-Inositol is converted into DCI by an insulin dependent NAD/NADH epimerase enzyme. It is known to be an important secondary messenger in insulin signal transduction. DCI accelerates the dephosphorylation of glycogen synthase and pyruvate dehydrogenase, rate limiting enzymes of non-oxidative and oxidative glucose disposal. DCI may act to bypass defective normal epimerization of myo-inositol to DCI associated with insulin resistance and at least partially restore insulin sensitivity and glucose disposal. One pilot study found males taking it had increased androgens and reduced estrogen.
Diabulimia, also known as ED-DMT1 in the US or T1ED in the UK, is an eating disorder in which people with type 1 diabetes deliberately give themselves less insulin than they need or stop taking it altogether for the purpose of weight loss. Diabulimia is not recognized as a formal psychiatric diagnosis in the DSM-5. Because of this, some in the medical or psychiatric communities use the phrases "disturbed eating behavior" or "disordered eating behavior" and disordered eating (DE) are quite common in medical and psychiatric literature addressing patients who have type 1 diabetes and manipulate insulin doses to control weight along with exhibiting bulimic behavior.
Glycogenic hepatopathy(also known as Mauriac syndrome ) is a rare complication of type 1 diabetes characterized by extreme liver enlargement due to glycogen deposition, along with growth failure and delayed puberty. It occurs in some children and adolescents with type 1 diabetes irrespective of their glycemic control.
Saroglitazar is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.
Archibald's sign refers to a feature in the hand characterized by a shortening of the fourth or/and fifth metacarpals when the fist is clenched.
Van Wyk and Grumbach syndrome is a medical condition defined by a combination of hypothyroidism, precocious puberty, and ovarian cysts in pre- and post-pubertal girls or macroorchidism in boys.
Shashank R. Joshi is an Indian endocrinologist, diabetologist and medical researcher, considered by many as one of the prominent practitioners of the trade in India. He was honoured by the Government of India, in 2014, by bestowing on him the Padma Shri, the fourth highest civilian award, for his services to the field of medicine. He is a part of the COVID-19 Task Force for the state of Maharashtra, India.
Nikhil Tandon is an Indian endocrinologist, medical academic and the head of the department of endocrinology, metabolism and diabetes at the All India Institute of Medical Sciences. He is a recipient of Dr. B. C. Roy Award, the highest Indian medical award in 2005 and was honoured by the Government of India in 2015 with Padma Shri, the fourth highest Indian civilian award.
India has an estimated 77 million people formally diagnosed with diabetes, which makes it the second most affected in the world, after China. Furthermore, 700,000 Indians died of diabetes, hyperglycemia, kidney disease or other complications of diabetes in 2020. One in six people (17%) in the world with diabetes is from India. The number is projected to grow by 2045 to become 134 million per the International Diabetes Federation.
The Madras Diabetes Research Foundation (MDRF) is a medical research organization located in Gopalapuram, Chennai. MDRF was established in 1996 by an eminent diabetologist, Dr. V. Mohan.
Sanjay Kalra is an Indian endocrinologist working at Bharti Hospital, Karnal, Haryana. Kalra is the Immediate Past President of Endocrine Society of India and Vice President of South Asian Federation of Endocrine Societies. He also serves on the executive council of the Research Society for Study of Diabetes in India. He has over 1000 PubMed indexed articles to his name, and has fostered bilateral and multilateral links between various Afro Asian countries in the field of endocrinology. He has developed the terms Glucocrinology and Lipocrinology. and the Gluco Coper tool to assess coping mechanisms. Winner of the DAWN Award (2009). He has also published the concepts of diabetes fatigue syndrome, euthymia in diabetes, quaternary prevention in endocrinology, and quinary prevention.
Endocrine & Metabolism Research Institute (EMRI) is one of Tehran University of Medical Sciences research institute with a mission to combine clinical care, research, and education in diabetes, endocrine and metabolic diseases.
Thyromimetic drugs are synthetic agonists of the thyroid hormone receptor's isoforms TR α1, TRα2, TRβ1, or TRβ2, mimicking some or all of the effects of endogenously produced thyroid hormones that regulate metabolism. Some thyromimetic drugs are selective for various of these receptors over others, enabling more targeted effects and reducing toxicity. Thyromimetics selective for TRβ—including eprotirome, sobetirome, resmetirom, and the prodrug VK2809—have been investigated for the treatment of non-alcoholic fatty liver disease, dyslipidemia, and other metabolic and neurodegenerative diseases.
Eprotirome is a thyromimetic drug that has been investigated for the treatment of dyslipidemia. A Phase III trial in humans was discontinued after the drug was found to have negative effects on cartilage in dogs.
Ghada El-Hajj Fuleihan is a professor of medicine, researcher and physician scientist at the American University of Beirut. Prior to that she held the position of founding Director of the Calcium Metabolism Program at Brigham and Women's Hospital. She is also the Bernard Lown Scholar in the Department of Global Health and Population at the Harvard T. H. Chan School of Public Health. In 2022, she became a member of the editorial board of Mayo Clinic Proceedings.
